Clinical trial
Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
NCT00176644 · University of Medicine and Dentistry of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00176644 |
|---|---|
| Title | Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer |
| Official title | Phase II Trial of Transdermal Estradiol in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Transdermal Estradiol |
| Enrollment | 23 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 13, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: